Data from COVID-19 randomized controlled trials (RCTs) may be used to develop clinical guidelines. It is important to understand differences between trial-eligible and real-world (RW) patients’ characteristics and outcomes. This objective of this presentation is to compare hospitalized COVID-19 patients who may meet key eligibility requirements for the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-4a) trial (RCT-eligible cohort) to patients without these criteria (RW-COVID cohort) and report unadjusted occurrence of invasive mechanical ventilation (IMV).
It was presented as a Lightning Forum at the 37th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.
Ashley I. Martinez, Silvia Perez-Vilar, Mayura Shinde, Maria E. Kempner, Joy Kolonoski, Sarah K. Dutcher, Brian Kit